Abstract. Current European and US guidelines for rHBV after HCT vary. The EBMT recommends rHBV starting 6-12 months after HCT (1). Immunization is optional in the CDC guidelines (2). Nevertheless, rHBV is required for re-entry to school and certain workplaces. To determine the immunogenicity of rHBV following HCT, the pre and post vaccine titers of 292 allogeneic transplant recipients who were immunized with rHBV were analyzed. Immunization was initiated in patients off immunosuppression who achieved specific minimal milestones of immune competence. Overall, 64% of patients seroconverted. In multivariate analyses, response was adversely affected by age >18 years (p<0.01) and history of prior chronic GVHD (p<0.0001) but not by donor type, use of T cell depletion, adoptive immunotherapy, or rituximab. By comparison, 89% of rHBV non-responders mounted a >3 fold rise in polio titers following three doses of inactivated poliovirus. These data demonstrate that the rate of seroconversion following rHBV is lower in allogeneic HCT recipients compared with age matched normal controls. The data emphasize the need to document pre and post vaccine titers to ensure response and suggest that immunization guidelines based on time interval from HCT, irrespective of immune competence, may not ensure adequate protection against certain vaccine preventable diseases.
Introduction
Liver disease secondary to hepatitis B virus (HBV) is a vaccine preventable disease (3, 4) . It is currently estimated that 1 to 1.3 million individuals living in the United States are chronically infected with Hepatitis B virus (HBV), five thousand of whom will die each year from liver failure or hepatocellular carcinoma (5) . In 1991, the Immunization Practices Advisory Committee (ACIP) recommended that all infants be vaccinated with rHBV starting at birth (6) . In 1999, this recommendation was expanded to include all children <18 years of age (7) . Immunization of infants, children, and young adults with three age-appropriate doses of rHBV is associated with a >95% seroconversion rate (8) . Approximately 85% of normal adults >40 years of age will also develop positive titers following rHBV (9) . The vaccine is less immunogenic in patients undergoing dialysis for end-stage renal disease, in patients with advanced liver disease due to Hepatitis C, and in individuals immunocompromised by HIV (reviewed in 10).
For personal use only. on . by guest www.bloodjournal.org From To date, a limited number of studies have evaluated the ability of HCT recipients to develop and maintain anti-HBs titers following rHBV (11) . In 1997, Li Volti and colleagues (12) evaluated anti-HBs titers in twenty hepatitis B virus seropositive patients with thalassemia who underwent an unmodified allogeneic transplant from an HLA-matched hepatitis B virus seronegative sibling. Fifty percent of patients, including nine who were previously immunized, became seronegative after HCT. Following two doses of the recombinant Hepatitis B virus vaccine, Engerix-B, all patients developed a rise in anti-HBs. Machado et al (13, 14) reported a 100% seroconversion rate in 5 autologous and 45 HLA-matched related HCT recipients immunized at least 1 year after transplant. Despite the excellent initial response, 60% of patients failed to sustain titers for more than 1 year following vaccination (13, 14) .
To determine the ability of allogeneic transplant recipients to respond to rHBV, the immunization records and pre and post vaccine titers of 292 patients vaccinated against HBV after an unrelated or related HCT were analyzed and compared to responses attained following vaccination with inactivated poliovirus (IPV). The effects of transplant type, patient age, stem cell and donor type, use of T cell depletion, history of prior acute or chronic graft versus host disease, as well as the use of donor leukocyte infusion (DLI) and/or humanized monoclonal anti-CD20 antibody, rituximab (15) on rates of seroconversion and duration of response were assessed.
Patients and Methods
This study was approved by the Memorial Sloan Kettering Institutional Review Board.
The medical records of all Hepatitis B surface antigen (HBsAg) negative patients who received an allogeneic HCT from a HBsAg negative donor at Memorial Sloan Kettering Cancer Center (MSKCC) from 1/1/92 through 4/15/04 and survived disease-free for >1 year were reviewed. Three hundred and seven patients were identified who received three recombinant DNA hepatitis B immunizations. Criteria for vaccination with rHBV and IPV at this center included a circulating CD4 cell count of >200 cells/uL, IgG level >500 mg/dl at least 8 weeks following the last dose of intravenous immune globulin, and in vitro T cell response to phytohemagglutinin >75% lower limit of normal. Patients with a prior history of GVHD (grade II-IV acute, limited or extensive chronic GVHD) were For personal use only. on . by guest www.bloodjournal.org From eligible for revaccination if they were off systemic immunosuppressive therapy and had minimal or no signs or symptoms attributable to GVHD (16, 17) . Patients who were Hepatitis C antibody positive but did not have severe liver disease at the time of vaccination were included in the analysis (n=7). Patients were vaccinated with an age appropriate dose of Recombivax HB (Merck & Co) or Engerix-B (SmithKline Beecham Pharmaceuticals) recommended by the manufacturer. The majority of patients were vaccinated at times 0,1, and 6 months. Seventy-six percent of patients were vaccinated at MSKCC. All patients were evaluated at MSKCC before and after vaccination including assessment of acute and chronic GVHD using established criteria (16) . 
Patient and transplant characteristics
Patient and transplant demographics are shown in Table 1 . The median patient age at transplant was 24 years, with a range of 0.2-69.0 years. The stem cell donor was an HLA-A, B, DRβ1 identical sibling, an HLA-mismatched family member, or unrelated donor in 65%, 9%, and 25% of cases, respectively. Sixty-five percent of patients received a T-cell depleted HCT. Bone marrow was T cell depleted by soybean lectin agglutination followed by rosetting with sheep red blood cells (n=149) (18) or treatment with the monoclonal antibody T10B9 and complement (n=6) as previously described (19) . G-CSF mobilized peripheral blood stem cells underwent positive selection for CD34+ stem cells followed by T cell depletion by rosetting with sheep erythrocytes (n=37). The only patients who received GVHD prophylaxis following a TCD HCT were the 6 recipients of an unrelated T10B9-treated BMT.
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The majority of recipients of a T-cell replete (unmodified) HCT (n=100) received cyclosporine A (CyA) and methotrexate (n=57) for GVHD prophylaxis. Two infants with Severe Combined Immunodeficiency Disease and one adult recipient of a syngeneic transplant did not receive GVHD prophylaxis after an HLA-matched related unmodified transplant. The remaining 40 patients received CyA (n=6) or methotrexate alone (n=3), CyA/steroids (n=3), CyA/methotrexate/steroids (n=7), CyA/Campath (n=8), CyA/mycophenolic acid (n=3), or tacrolimus and methotrexate (n=10).
Twenty-five (8.6%) of the 292 patients received the monoclonal antibody rituximab for the treatment of a post transplantation EBV lymphoproliferative disorder (EBV-LPD) (n=8), EBV viremia (n=12), autoimmune cytopenia (n=2 ), or recurrent lymphoma (n=3).
Sixty-five patients received adoptive immunotherapy in the form of unfractionated donor lymphocytes for the treatment or prevention of an EBV-LPD (n=13), to prevent or treat recurrent malignancy (n=43), an autoimmune cytopenia (n=1), mixed T cell chimerism (n=4), or to promote immune reconstitution (n=4)
Statistical analysis
Frequency distributions of characteristics of patients who responded to rHBV or IPV, and the study cohort were summarized. Univariate and multivariate logistic regression analysis was used to examine the odds ratio for differences between vaccine responders and non-responders. The Cuzick (20) test for nonparametric trends across ordered groups was used to determine the effect of age categories on seroconversion rates. All statistical tests were considered significant at a two-sided α -level of 0.05. Statistical analyses were performed using Stata 7 (21) .
Results
The median time to initiate vaccination against Hepatitis B was 23.4 months (range: 5.3-101.6) post HCT. There was no significant difference in the time to vaccination in Tdepleted versus T-cell replete transplant recipients (23.5 months versus 22.5 months).
In patients less than or greater than 18 years of age, the median time to vaccination was 20.0 and 24.5 months after HCT, respectively. This reflected in part the time to achieve immune milestones required for revaccination in children and adults following HCT. Overall, 171 (64%) of 267 patients seroconverted after vaccination (Table 2) , including seventy-two of 99 (72%) children and 99 of 168 (60%) adults (p=0.02). There were no significant differences in the proportion of responders on the basis of pre-transplant diagnosis, stem cell source (bone marrow or peripheral blood), donor type, use of T cell depletion, inclusion of total body irradiation in the conditioning regimen, or seropositive donor ( Table 2) . In univariate analysis, younger age at transplantation (p<0.0001) and at initial immunization was associated with significantly higher rates of seroconversion fold rise in titer against all three polio serotypes after receipt of three IPV given at two month intervals, including 70 (89%) of the 79 non-rHBV responders. Only younger age at transplant (p=0.01) was associated with improved response to IPV (Table 3 ).
Although the number of patients is small, the poorest response to rHBV vaccine was observed in recipients of an HLA-mismatched related HCT, irrespective of prior GVHD or use of T cell depletion. Following an HLA mismatched related HCT, 56% of patients developed positive anti-HBs titers, compared to 63.8% and 64.8% of recipients of an HLA-matched related or unrelated HCT, respectively. Within all HCT groups, there was a trend for decreasing seroconversion with increasing patient age, p = 0.04 (Table   4 ). There were no significant differences in responses among recipients of a TCD or For
Ninety-six patients failed to respond to immunization with three rHBV. After failing a primary series, 31 patients were re-vaccinated with rHBV. Although no patient responded to a single booster vaccine, 17 (55%) patients responded after receiving an additional three rHBV.
Discussion.
Over the last decade improved disease-free survival following HCT has resulted in increasing numbers of HCT survivors returning to school and jobs which require vaccination against Hepatitis B prior to re-entry. Whereas vaccination of healthy children and young adults is considered protective against vaccine preventable diseases due to the greater than 90% seroconversion rates observed, the ability of HCT patients to respond to childhood vaccines is less well studied. Moreover, the immunogenicity of vaccinations in recipients of an HLA-unrelated or HLA-mismatched, related HCT or T-cell depleted HCT, remains largely unknown (reviewed in 11).
Our data demonstrate that 64% of patients vaccinated against hepatitis B post HCT develop protective titers. The immunogenicity of the recombinant vaccine is decreased, however, in patients >18 years of age when compared with age matched controls and in patients with a history of Grade II-IV acute GVHD or chronic GVHD. In a smaller study of allogeneic or autologous HCT recipients, Machado et al. also found an association of older age and prior chronic GVHD with poorer response to rHBV vaccination (14) . Similar to reports in normal controls, approximately 50% of allogeneic transplant recipients who fail an initial series of rHBV, will respond to a second series (3) . In contrast to the results of rHBV, response to polio virus was excellent in all age groups and not adversely affected by prior acute or chronic GVHD. Ninety-six percent of patients responded to IPV.
The greater response to IPV likely reflects in part the multiple antigenic peptides included in the Salk vaccine compared to the single small envelope (S protein) contained in recombinant Hepatitis B vaccines currently licensed in the US (reviewed in 3). It is also possible that responses reflect expansion of memory T and B cells persisting after childhood immunization, which were transferred in the unmodified or even the T cell depleted grafts.
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The impact of age and prior chronic GVHD on hepatitis B responses observed in this study occurred despite our requirement that patients be off all immunosuppressive medications and that they had achieved specific minimal milestones of T and B cell immune competence. Our rationale for this approach was based on concerns that vaccination prior to the development of these milestones would be less effective in inducing immediate and long-term T and B cell responses. Indeed, qualitative and quantitative differences in effector and memory helper T and/or B cells may differentiate long-term responders and non-responders (22, 23) . Although all HCT recipients are subject to a varying period of T and B lymphocytopenia and subsequent functional incompetence despite return of normal numbers of T and B cells, the severity and duration of this immunoincompetence is not uniform across transplant types and or patients of all ages (24, 25) . For these reasons, we hypothesized that immunization guidelines based on fixed times after HCT (1,2) are unlikely to result in adequate protection against vaccine preventable diseases in all patient groups. Indeed, based on studies from our own series and that of others ( 13, 14) vaccination with rHBV starting at 6 or 12 months following HCT, particularly in older adults, will likely precede reconstitution of required memory and effector lymphoid populations necessary for longterm immunity (22, 23) . In the study of Machado et al 60% of patients vaccinated lost protective anti-HBs titers by one year following immunization (14) . In contrast, in our own study in which patients were immunized only after recovering a specific level of immune reconstitution (which varied in time from 6 months to >2 years) only 20% of patients lost protective levels of antibody by 5 years after immunization. Clearly differences in several variables such as age, incidence and severity of acute and/or chronic GVHD, and/or the type of transplant might contribute to these differences. However, differences in the durability of the response do underscore the need for prospective studies to examine and compare the effectiveness of current vaccination protocols.
Studies in normal individuals have demonstrated that at least 60% of children vaccinated as infants and 98% of young adults vaccinated in adolescence retain protective titers 10 years following HepB vaccination (26) . The 1990 measles epidemic in the United States (reviewed in 27), the spread of measles in a BMT unit in Sao Paolo (28) , the outbreak of varicella in a daycare center (29) in which the index case and the majority of affected children had previously received Varivax, and the recent increase in pertussis in normal (30) individuals and oncology patients (31) 
